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l e t t e r s t o t h e e d i t o r
The Importance of Good Data, Analysis,
and Interpretation for Showing the
Economics of Reducing Healthcare-
Associated Infection
To the Editor—In a recent review article in Infection Control
and Hospital Epidemiology, Umscheid et al1 summarized pub-
lished data on incidence rates of catheter-associated blood-
stream infection (CABSI), catheter-associated urinary tract
infection (CAUTI), surgical site infection (SSI), and venti-
lator-associated pneumonia (VAP); estimated how many cases
are preventable; and calculated the savings in hospital costs
and lives that would result from preventing all preventable
cases. Providing these estimates to policy makers, political
leaders, and health officials helps to galvanize their support
for infection prevention programs. Our concern is that im-
portant limitations of the published studies on which Um-
scheid and colleagues built their findings are incompletely
addressed in this review. More attention needs to be drawn
to the techniques applied to generate these estimates.
The ambitious goal of Umscheid and colleagues was to
synthesize all evidence on the effectiveness of interventions
to prevent CABSI, VAP, CAUTI, and SSI. The scope of this
review might be too broad to allow a sufficiently detailed
appraisal of the evidence found. Preventability is a moving
target because technologies and behaviors change, and in-
ferences about causal effects depend on an explicit specifi-
cation of alternatives.2 Other evidence synthesis studies for
infection control interventions have been narrower in scope
and more cautious in interpreting the data. Gould et al3 reg-
istered a review of the effectiveness of hand hygiene inter-
ventions with the Cochrane Collaboration. Of 48 articles and
1 thesis revealed by the search strategy, only 2 studies were
included. The rest were excluded because they were small
scale or poorly controlled or because their long-term impacts
were not assessed. Some of the studies included by Umscheid
et al that report infection control effectiveness had significant
methodological flaws. Harris et al4 discuss the challenges that
researchers face when trying to estimate the effectiveness of
infection prevention.
The information that Umscheid et al use to estimate the
annual number of infections should be treated with caution.
Large variability in the quality of infection surveillance data
for CABSI was found by Lin et al.5 Whether other types of
infection are surveyed with greater accuracy is unknown.
None of the studies used to estimate the clinical and eco-
nomic consequences of these infections appropriately ac-
counted for length of stay or risk of death, either because the
timing of infection was ignored altogether or because of con-
ditioning on the future.6 The consequence is that results are
biased upward.7 Barnett et al8 showed that 11.23 extra days
in the hospital were attributable to a case of healthcare-
associated infection when the timing of infection was ignored
and that, when the timing of infection was appropriately
included, the additional duration of hospital stay was reduced
to 1.35 days. Problems of bias may also arise when attributing
death risk to infection.
Umscheid et al used cost data prepared by hospital ac-
countants to make an economic argument. This is inappro-
priate, because accountants and economists have different
objectives and require different information.9 Accounting
costs are unlikely to capture the opportunity cost of infec-
tions. The alternate use of resources released from reduced
infection is easily misinterpreted when presented as cash sav-
ings to hospitals.10
The findings of Umscheid et al1 were that between 23,545
and 53,483 lives would be saved every year as a result of
preventing preventable cases of CABSI, VAP, CAUTI, and SSI.
Annual cost savings to hospitals would be between $3.43
billion and $23.44 billion. Using a conservative estimate of
$5.5 million per statistical life saved,11 the total economic
benefit from eliminating preventable infections suggested to
policy makers is between $136 billion and $341 billion an-
nually. We suggest that flaws in the underlying data used to
make these estimates exaggerate the result and will improperly
raise expectations about the value of future investments in
prevention programs. A potential negative consequence for
the infection control community is reduced credibility. An-
other risk associated with reporting such large numbers is
that government health regulators might use them to justify
withholding large cash reimbursements to hospitals when
(preventable) infections do happen, and this might create an
economic incentive to underreport infections,12 which is a
quality-reducing activity.
Relentless growth in healthcare costs means that decision
makers will demand high-quality economic evidence prior to
committing resources to healthcare programs. Reliable eco-
nomic arguments are important for obtaining extra resources
and even for keeping existing ones. Those working toward
reducing the number of infections should carefully craft eco-
nomic arguments on the basis of sound methods and good
quality data,13 and they should use the evidence base to build
sustainable and cost-effective infection control programs.
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Reply to Graves et al
To the Editor—We appreciate the interest by Graves et al1
regarding our recent article estimating the proportion of
healthcare-associated infections (HAIs) that are reasonably
preventable and the related mortality and costs.2 In their let-
ter, Graves and colleagues suggest that our estimates were
intended to galvanize support for infection prevention pro-
grams and were generated using studies with important lim-
itations. We wish to address these concerns in this response.
Our analysis was originally performed in 2008 for the So-
ciety for Healthcare Epidemiology of America (SHEA), to be
included in its written testimony on HAIs to Congress.3 To
inform its testimony, SHEA requested that we review the
published literature to estimate the proportion of HAIs that
might be preventable. This was a critical question, because
the federal government was considering a policy of nonpay-
ment for HAIs as an incentive to reduce HAIs.4 Although
some believed this was an effective strategy to reduce HAIs,
others were concerned that not all HAIs were preventable
and that the incentive under consideration would present
challenges to hospitals caring for patients at high risk for
HAIs.5 To estimate the proportion of preventable HAIs in the
most efficient and accurate manner, we used an up-to-date
federally funded systematic review that examined the effec-
tiveness of single and multimodal interventions on HAI pre-
vention6 as well as the most recent and valid estimates of
HAI incidence.7 We also conducted our own systematic review
of studies examining the incremental costs of individual
HAIs.2 The dilemma at the time was whether to make an
estimate based on data of limited quality or to avoid making
such an estimate because of the data limitations and take the
chance that other estimates derived using a less scientific
approach would inform the policy discussion. SHEA opted
to inform the discussion with the best estimates available from
the published literature, so the intent of our analysis and our
subsequent article was to present those estimates while high-
lighting their key limitations and caveats.
To ensure that we provided the most accurate and gen-
eralizable data on the effectiveness of HAI prevention inter-
ventions, we estimated ranges of preventability and included
the lowest and highest risk reductions reported by only those
studies that were conducted in the United States, were pub-
lished within the previous 10 years, and received a quality
score of moderate or good from the federally sponsored sys-
tematic review.6 Of the 64 studies originally included in the
